EMBL Grenoble’s Cusack group has made breakthroughs in understanding the XIAP/RIPK2 complex, crucial for treating inflammatory bowel diseases. Their research shows how RIPK2 kinase binds with XIAP, impacting gut inflammation and bacteria control. This discovery, significant for IBD and potential cancer treatments, aids in developing new therapeutics and supports collaborations for RIPK2 inhibitor development.
Reference: André M. A promising target to fight inflammatory bowel diseases. EMBL. Updated October 26, 2023. Accessed December 20, 2023. https://www.embl.org/news/science/a-promising-target-to-fight-inflammatory-bowel-diseases/
Link: https://www.embl.org/news/science/a-promising-target-to-fight-inflammatory-bowel-diseases/
